Notably, clinical trials report BAFF reduction in SLE patients following HCQ treatment [72, 73]potentially through lysosomal alkalinization-mediated inhibition of type I IFN signaling and subsequent BAFF mRNA downregulation [74]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.